drugset / Trial / NCT00855972
Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome
Withdrawn
Stanford University
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to obtain data or information on the safety and effectiveness of low dose naltrexone (LDN) for treating the symptoms of juvenile primary fibromyalgia syndrome. This is a dose finding study to find whether LDN helps the symptoms of juvenile fibromyalgia, and at what dose it does so.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-12
- Completion
- 2011-12
Outcome
Outcome not reported
Stopped: “The FDA IND application is paused due to additional required testing. The IRB protocol was closed prior to research starting.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naltrexone | Small molecule | — | — |